Welcome to the AYC website

Bespoke business development, market analysis and commercial support for life science and pharmaceutical enterprises
  • When do we start?

  • Who do we talk to?

  • How do I build and defend my value proposition?

  • Which type of deal is best for my company?

  • How much is it worth?


The commercialisation of life science assets, whether through licensing, divestment, sales or the provision of services is a challenge for companies at all stages of their development. The process can be particularly daunting for early-stage enterprises, where the unproven and high-risk nature of early assets can complicate crystalisation of their value and commercialisation activities must compete with other demands made on management time and resource.

 

Effective commercialisation is arguably the most critical of all company activities.  A license or other deal serves to validate your value proposition and has a strategic value which can outweigh any immediate financial benefit. Third-party “buy-in” to your technology or product candidate can smooth the path to further investment and act as a catalyst for additional commercial interactions.

 

Converting passing interest into agreements requires vision, preparedness and clarity of purpose. Commercial agreements are not concluded for a variety of reasons, but all of the most commonly cited deal breakers, such as unrealistic financial expectation, delay and misrepresentation or misinterpretation of market data can be avoided long before negotiations begin.
 
For the past 26 years, Alexander Yule Consulting has assisted life science and pharmaceutical companies to define and make the most of their value proposition, to expedite the commercialisation process through prospect identification, market forecasting, valuation, term sheet provision and general commercial and corporate support.
 
“Luck is what happens when preparation meets opportunity” 
(Lucius Annaeus Seneca)

 


Comments